NRX Pharmaceuticals (NRXP) Times Interest Earned (2017 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly Times Interest Earned came in at -$20.35 in Q1 2026, up 4.41% on a QoQ basis from -$21.29 in Q3 2025.
NRX Pharmaceuticals (NRXP) Times Interest Earned (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 8 years of Times Interest Earned data on file, last reported at -$20.35 in Q1 2026.
- On a quarterly basis, Times Interest Earned changed N/A year-over-year to -$20.35 in Q1 2026; TTM through Mar 2026 was -$73.48, a 104.01% decrease from a year earlier, with the FY2025 full-year figure at -$0.32, up 14.94% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$20.35, up from -$21.29 in the prior quarter.
- Over the last five years, Times Interest Earned for NRXP reached as high as -$3.88 in Q4 2022 and fell as low as -$178.0 in Q2 2023.
- Historically, Times Interest Earned has averaged -$40.09 across 5 years, with a median of -$21.29 in 2025.
- On a YoY basis, Times Interest Earned climbed as much as 99.99% in 2022 and fell as far as 6526.46% in 2022.
- Year by year, Times Interest Earned stood at -$3.88 in 2022, then plunged by 1319.76% to -$55.08 in 2023, then soared by 70.88% to -$16.04 in 2024, then slumped by 32.76% to -$21.29 in 2025, then grew by 4.41% to -$20.35 in 2026.
- Per Business Quant data, the three most recent Times Interest Earned figures were -$20.35 in Q1 2026, -$21.29 in Q3 2025, and -$16.04 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,930.72 Bn | 1,930.66 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.36 Bn | 466.57 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 123.47 Bn | 116.22 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.52 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.00 Bn | 62.00 Bn | - | - |
| 8 | Argenx Se | 56.08 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 3.88 |
| 10 | NRX Pharmaceuticals | 118.31 Mn | 111.61 Mn | 437,000.00 | -20.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.35 |
| Sep 30, 2025 | -21.29 |
| Mar 31, 2024 | -16.04 |
| Dec 31, 2023 | -55.08 |
| Sep 30, 2023 | -11.62 |
| Jun 30, 2023 | -178.00 |
| Mar 31, 2023 | -31.02 |
| Dec 31, 2022 | -3.88 |
| Sep 30, 2022 | -32.88 |
| Jun 30, 2022 | -55.17 |
| Mar 31, 2022 | -15.61 |
| Dec 31, 2021 | -26,487.50 |
| Sep 30, 2021 | -1.61 |
| Jun 30, 2021 | -0.83 |
| Mar 31, 2021 | -0.84 |
| Dec 31, 2020 | -805.76 |
| Sep 30, 2020 | -411.51 |
| Jun 30, 2020 | 41.40 |
| Dec 31, 2017 | -6.10 |